ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will
present at the Cowen and Company 29th Annual Healthcare
Conference Monday, March 16 at 4:40 p.m. Eastern Time. A live webcast of
the presentation may be accessed at the ARYx website http://www.aryx.com.
The presentation will be archived for 90 days.
About ARYx Therapeutics, Inc.
ARYx Therapeutics is a biopharmaceutical company focused on developing a
portfolio of internally discovered products designed to eliminate known
safety issues associated with well-established, commercially successful
drugs. ARYx uses its RetroMetabolic Drug Design technology to design
structurally unique molecules that retain the efficacy of these original
drugs but are metabolized through a potentially safer pathway to avoid
specific adverse side effects associated with these compounds. ARYx
currently has four products in clinical trials: an oral anticoagulant
agent for patients at risk for the formation of dangerous blood clots,
tecarfarin (previously ATI-5923); an oral anti-arrhythmic agent for the
treatment of atrial fibrillation, budiodarone (previously ATI-2042); a
prokinetic agent for the treatment of various gastrointestinal
disorders, ATI-7505; and, an agent for the treatment of schizophrenia
and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com
for additional information.
ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 ext. 211
Vice
President Corporate Affairs
